Market Place
Sourcing Support
Crescendo announces first U.S. patients dosed in Phase 1b trial of CB307
06 Dec 2023 //
GLOBENEWSWIRE
Crescendo Biologics Secures $32M to Expand CB307 Trial
25 Jul 2023 //
CONTRACT PHARMA
Crescendo secures $32M and announces expansion of CB307 Ph 1b trial
24 Jul 2023 //
BUSINESSWIRE
Angle PLC, Crescendo Biologics Ink Clinical Services Contract
13 Apr 2023 //
CONTRACT PHARMA
Angle PLC Announces Pharma Services Contract with Crescendo Biologics
13 Apr 2023 //
ACCESSWIRE
BioNTech builds to a Crescendo with $750M cancer research pact
10 Jan 2022 //
FIERCEBIOTECH
ICR in new collaboration to develop ‘next generation’ immunotherapy candidate
13 Dec 2021 //
ICRNEWSUK
Zai Lab Achieves Proof-of-Concept for ZL-1102 in a Phase 1b Trial in Psoriasis
21 Oct 2021 //
BUSINESSWIRE
Crescendo Biologics Announces Prestigious New Collaboration Institute of Cancer
20 Oct 2021 //
BUSINESSWIRE
Crescendo to Participate in Upcoming Investor Events
07 Jul 2021 //
BUSINESSWIRE
Crescendo Biologics Expands its Ongoing Collaboration with Takeda
10 Dec 2020 //
BUSINESSWIRE
Crescendo Biologics expands Takeda collaboration
09 Dec 2020 //
PHARMATIMES
Crescendo Biologics & Cancer Research UK sign Clinical Dev Partnership to CB213
05 May 2020 //
CRESCENDOBIOLOGICS
Crescendo links with CRUK to progress cancer therapy
05 May 2020 //
PHARMATIMES
Crescendo Biologics & Cancer Research UK sign Clinical Dev Partnership CB213
05 May 2020 //
BUSINESSWIRE
Crescendo Biologics Reaches Fifth Milestone in its Strategic Collabo with Takeda
23 Sep 2019 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.